AREV Life Sciences Global Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

AREV Life Sciences Global yıllık ortalama 48.7% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 46% annual. Gelirler yılda ortalama 10.2% oranında büyüyor .

Anahtar bilgiler

48.7%

Kazanç büyüme oranı

51.5%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	23.1%
Gelir büyüme oranı	10.2%
Özkaynak getirisi	n/a
Net Marj	-555.8%
Son Kazanç Güncellemesi	30 Sep 2022

Yakın geçmiş performans güncellemeleri

Recent updates

How Much Are AREV NanoTec Brands Inc. (CSE:AREV) Insiders Taking Off The Table?

Jan 02

Gelir ve Gider Dağılımı

AREV Life Sciences Global nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

CNSX:AREV Gelir, gider ve kazançlar (CAD Millions )
Tarih	Kazançlar	G+A Giderleri	Ar-Ge Giderleri
30 Sep 22	-1	2	0
30 Jun 22	-1	2	0
31 Mar 22	-1	2	0
31 Dec 21	-1	2	0
30 Sep 21	-2	1	0
30 Jun 21	-2	1	0
31 Mar 21	-2	1	0
31 Dec 20	-1	1	0
30 Sep 20	-1	0	0
30 Jun 20	-1	1	0
31 Mar 20	-2	2	0
31 Dec 19	-3	2	1
30 Sep 19	-10	2	1
30 Jun 19	-10	3	1
31 Mar 19	-9	1	1
31 Dec 18	-8	1	0
30 Sep 18	-2	1	0
30 Jun 18	-1	1	0
31 Mar 18	-1	1	0
31 Dec 17	-1	1	0
30 Sep 17	-1	1	0
30 Jun 17	0	0	0
31 Mar 17	0	0	0
31 Dec 16	0	0	0
30 Sep 16	0	0	0
30 Jun 16	0	0	0
31 Mar 16	0	0	0
31 Dec 15	0	0	0
30 Sep 15	0	0	0
30 Jun 15	0	0	0
31 Mar 15	0	0	0
31 Dec 14	0	0	0
30 Sep 14	0	0	0
30 Jun 14	0	0	0
31 Mar 14	0	0	0
31 Dec 13	0	0	0
30 Sep 13	0	0	0
30 Jun 13	0	0	0
31 Mar 13	0	0	0

Kaliteli Kazançlar: AREV şu anda kârlı değil.

Büyüyen Kar Marjı: AREV şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: AREV 'un son 5 yılda yıllık kazanç büyüme oranının pozitif olup olmadığını belirlemek için yeterli veri yok.

Büyüme Hızlandırma: AREV 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: AREV kârlı olmadığından, geçmiş yıl kazanç büyümesinin Pharmaceuticals sektörüyle ( -40.8% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: AREV 'un yükümlülükleri varlıklarından fazla olduğundan Özsermaye Getirisi'ni hesaplamak zordur.

AREV Life Sciences Global Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Third quarter 2022 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 3Q 2021)

Second quarter 2022 earnings released: CA$0.026 loss per share (vs CA$0.028 loss in 2Q 2021)

Full year 2021 earnings released: CA$0.051 loss per share (vs CA$0.068 loss in FY 2020)

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

Second quarter 2021 earnings released: CA$0.028 loss per share (vs CA$0.017 loss in 2Q 2020)

First quarter 2021 earnings released: CA$0.026 loss per share (vs CA$0.012 loss in 1Q 2020)

Recent updates

AREV Life Sciences Global Corp., Annual General Meeting, Apr 05, 2024

No independent directors

No independent directors

No independent directors

AREV Life Sciences Global Corp. Announces the Resignation of Melvin Maxwell from Board

No independent directors

Third quarter 2022 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 3Q 2021)

Chairman & CEO recently bought CA$59k worth of stock

No independent directors

AREV Life Sciences Global Corp. Announces Management Changes

Second quarter 2022 earnings released: CA$0.026 loss per share (vs CA$0.028 loss in 2Q 2021)

AREV Life Sciences Global Corp. Announces the Appointment of Sateesh Apte to the Scientific Advisory Board

Full year 2021 earnings released: CA$0.051 loss per share (vs CA$0.068 loss in FY 2020)

No independent directors

AREV Life Sciences Global Corporation Appoints Brian V. Elliott to its Board of Directors

AREV Life Sciences Global Corp. Appoints Kevin Phelps as Chief Operating Officer

AREV Life Sciences Global Corp. Appoints Douglas Sorocco to Its Scientific Advisory Committee

AREV Life Sciences Settles Pending Litigation with Harvey

Third quarter 2021 earnings: Revenues and EPS in line with analyst expectations

AREV Life Sciences Global Corp. (CNSX:AREV) acquired Wright and Well Essentials Inc. for CAD 0.02 million.

Chairman & CEO exercised options to buy CA$200k worth of stock.

Chairman & CEO recently sold CA$125k worth of stock

Second quarter 2021 earnings released: CA$0.028 loss per share (vs CA$0.017 loss in 2Q 2020)

First quarter 2021 earnings released: CA$0.026 loss per share (vs CA$0.012 loss in 1Q 2020)

AREV NanoTec Brands Inc. Expands Extraction Results to Clinical Characterization of Compounds, Development of Advanced-Stage Therapeutic Foods and Discovery of Plant-Based Drugs

AREV NanoTec Brands Inc. announced that it has received CAD 0.67 million in funding

Arev Nanotec Brands Inc. Appoints Chad S. Johnson, Esq. as Special Counsel for Corporate Development

AREV NanoTec Brands Inc. Announces Addition of Kevin J. Phelps to its Board of Directors

AREV NanoTec Brands Inc. Appoints Dr. Jay Noller to its Scientific Advisory Board

AREV’s Nanotech Initiates Early-Stage Antiviral Photochemistry Derivation Discovery Program for Pandemic Viral Pathogens

New 90-day high: CA$0.42

AREV Appoints Dr. Roscoe Moore to Join the Advisory Board

AREV NanoTec Brands Inc. Corporate Update on Latest Innovation

AREV NanoTec Brands Inc. Appoints Dr. Uma V. A. Dhanabalan as Advisory Board

AREV NanoTec Brands Inc. announced that it expects to receive CAD 0.725 million in funding

AREV NanoTec Brands Inc. announced that it has received CAD 0.1 million in funding from Chiron Partners LLC

How Much Are AREV NanoTec Brands Inc. (CSE:AREV) Insiders Taking Off The Table?

New 90-day high: CA$0.22

Chairman & CEO recently sold CA$261k worth of stock

AREV NanoTec Brands Inc. Receives Its First Trial Run of Its Naturvac Immune Boost

AREV NanoTec Brands Inc. Appoints Don Shaxon to the Position of VP Marketing

First half earnings released

AREV Brands International Ltd. (CNSX:AREV) cancelled the acquisition of 5,300 square foot facility and a 100 acre cannabis and hemp cultivation in California.

AREV NanoTec Brands Inc. announced that it expects to receive CAD 0.16 million in funding

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin